Biocept (BIOC) Stock Price
Biocept Price
Revenue has compounded at 72.6% per year over the past 10 years to 25.86 M USD. Biocept's net margin stands at -124.1%, up from -775.7% several years earlier. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Biocept stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biocept over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biocept stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biocept's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biocept Price |
|---|
Biocept Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocept Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 3.00 | 5.00 | 3.00 | 5.00 | 27.00 | 61.00 | 25.00 | 2.00 | 6.00 | 21.00 | 21.00 |
| – | – | – | – | – | – | 66.67 | -40.00 | 66.67 | 440.00 | 125.93 | -59.02 | -92.00 | 200.00 | 250.00 | – |
| – | – | – | – | – | -100.00 | -80.00 | -200.00 | -100.00 | 22.22 | 37.70 | -8.00 | -8.00 | -8.00 | -8.00 | -8.00 |
| -2.00 | -1.00 | -2.00 | -2.00 | -3.00 | -3.00 | -4.00 | -6.00 | -5.00 | 6.00 | 23.00 | -2.00 | -0.16 | -0.48 | -1.68 | -1.68 |
| -12.00 | -10.00 | -7.00 | -13.00 | -16.00 | -18.00 | -21.00 | -24.00 | -23.00 | -15.00 | -2.00 | -31.00 | -24.00 | -23.00 | -17.00 | -3.00 |
| – | – | – | – | – | -600.00 | -420.00 | -800.00 | -460.00 | -55.56 | -3.28 | -124.00 | -1,200.00 | -383.33 | -80.95 | -14.29 |
| -13.00 | -12.00 | -9.00 | -15.00 | -16.00 | -18.00 | -21.00 | -25.00 | -25.00 | -17.00 | -2.00 | -32.00 | -100.00 | -25.00 | -15.00 | -8.00 |
| – | -7.69 | -25.00 | 66.67 | 6.67 | 12.50 | 16.67 | 19.05 | – | -32.00 | -88.24 | 1,500.00 | 212.50 | -75.00 | -40.00 | -46.67 |
| 0.57 | 0.57 | 0.57 | 0.57 | 0.02 | 0.03 | 0.09 | 0.28 | 2.07 | 11.85 | 0.49 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biocept generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biocept retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biocept's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biocept has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biocept's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biocept stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocept Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocept business model & stock analysis
Biocept SWOT Analysis
Strengths
• Strong expertise in liquid biopsy testing, providing a non-invasive method for cancer detection.
• Proprietary Target Selector™ technology enables efficient capture and analysis of tumor biomarkers.
• Collaborative partnerships with leading pharmaceutical companies for biomarker development.
• Well-established network of clinical laboratories ensuring reliable and timely diagnostic results.
• Dependency on a limited number of large contracts, making revenue vulnerable to contract renewals.
• High research and development costs for continuous innovation and enhancement of testing methodologies.
• Limited market presence compared to larger competitors in the molecular diagnostics industry.
• Price sensitivity among potential customers, as liquid biopsy testing may be perceived as expensive.
• Growing market demand for liquid biopsy testing due to its non-invasiveness and potential for early cancer detection.
• Emerging diagnostic partnerships and collaborations opening opportunities for expanding product portfolio.
• Increasing adoption of personalized medicine, creating a need for advanced molecular diagnostics.
• Potential to penetrate untapped markets by expanding distribution networks and strategic alliances.
• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.
• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.
• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.
• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.
Weaknesses
• Dependency on a limited number of large contracts, making revenue vulnerable to contract renewals.
• High research and development costs for continuous innovation and enhancement of testing methodologies.
• Limited market presence compared to larger competitors in the molecular diagnostics industry.
• Price sensitivity among potential customers, as liquid biopsy testing may be perceived as expensive.
• Growing market demand for liquid biopsy testing due to its non-invasiveness and potential for early cancer detection.
• Emerging diagnostic partnerships and collaborations opening opportunities for expanding product portfolio.
• Increasing adoption of personalized medicine, creating a need for advanced molecular diagnostics.
• Potential to penetrate untapped markets by expanding distribution networks and strategic alliances.
• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.
• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.
• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.
• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.
Opportunities
• Growing market demand for liquid biopsy testing due to its non-invasiveness and potential for early cancer detection.
• Emerging diagnostic partnerships and collaborations opening opportunities for expanding product portfolio.
• Increasing adoption of personalized medicine, creating a need for advanced molecular diagnostics.
• Potential to penetrate untapped markets by expanding distribution networks and strategic alliances.
• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.
• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.
• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.
• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.
Threats
• Intense competition from established players and new entrants in the liquid biopsy and molecular diagnostics space.
• Strict regulatory requirements and ongoing changes in healthcare policies may impact market accessibility.
• Rapid technological advancements increasing the risk of developing more cost-effective alternatives.
• Economic downturns and market fluctuations affecting healthcare budgets and investment in diagnostic services.
Biocept Segments
Biocept Revenue by Segment (1/3)
3 Years
Max
Details
Biocept Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Biocept Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Biocept Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Biocept Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biocept historical P/E ratio, EBIT multiple, and P/S ratio
Biocept annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biocept shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocept stock splits
Current Biocept forecasts and price targets in July 2026
Analyst Price Targets 2026| Δ MOM Price Target | 0.00 % |
| Buy | 75.00 % (6) |
| Hold | 25.00 % (2) |
| Sell | 0.00 % (0) |
| 12M Price Target | 4.08 |
| Last Price | 0.00 |
| Currency | USD |
| 12M Return Potential | 0 % |
| LTM Return | 0 % |
Biocept Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 3/29/2023 | -0.23USD | 5.58 MUSD | 2022 Q4 |
| 11/29/2022 | -0.20USD | 9.67 MUSD | 2022 Q3 |
| 11/10/2022 | -0.16USD | 12.66 MUSD | 2022 Q2 |
| 5/23/2022 | -0.14USD | 11.66 MUSD | 2022 Q1 |
| 4/5/2022 | -0.19USD | 11.27 MUSD | 2021 Q4 |
| 11/15/2021 | 0.07USD | 16.31 MUSD | 2021 Q3 |
| 8/16/2021 | -0.16USD | 9.89 MUSD | 2021 Q2 |
| 3/29/2021 | -0.28USD | 12.51 MUSD | 2020 Q4 |
| 11/12/2020 | -0.48USD | 2.54 MUSD | 2020 Q3 |
| 8/12/2020 | -0.51USD | 1.32 MUSD | 2020 Q2 |
Biocept shareholder structure
| % | Name |
|---|---|
0.76105% | |
0.25235% | |
0.13235% | |
0.03031% | |
0.02959% | |
0.00152% |
Biocept Supply Chain
Biocept Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | Kadmon Holdings, Inc. | -0.78 | -0.75 | -0.89 | -0.84 | — | |
| 2 | 0.73 | -0.53 | -0.63 | -0.81 | -0.80 | ||
| 3 | 0.82 | 0.18 | 0.85 | -0.12 | -0.67 | ||
| 4 | 0.09 | 0.70 | 0.91 | 0.54 | -0.64 | ||
| 5 | 0.76 | 0.57 | 0.83 | 0.44 | -0.63 |
Frequently asked questions about Biocept
Biocept Inc. operates as a molecular diagnostics company. Its business model revolves around developing and commercializing proprietary circulating tumor cell and circulating tumor DNA assays to provide physicians with insights for treating and monitoring cancer patients. By utilizing patented technologies, Biocept's liquid biopsy tests detect and analyze tumor-associated biomarkers from a simple blood sample. This enables healthcare providers to make informed decisions regarding the selection of targeted therapies, monitoring treatment response, and detecting the development of resistance mutations in cancer patients. Biocept aims to improve patient outcomes and contribute to advancing precision medicine in oncology.
Biocept stock
All fundamentals and in-depth analysis of Biocept
Our stock analysis for Biocept stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocept. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.